
Eiko Lifesciences Ltd is Rated Sell
2026-04-21 10:10:03Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 April 2026, providing investors with the most up-to-date view of the company’s performance and outlook.
Read More
Eiko Lifesciences Ltd is Rated Sell
2026-04-10 10:10:03Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Eiko Lifesciences Ltd is Rated Sell
2026-03-30 10:10:02Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
27-May-2026 | Source : BSENewspaper publication dated 27th May 2026 for Audited Financial Results (Standalone & Consolidated) of the Company for the Quarter and Year ended 31st March 2026 approved by the Board at their meeting held on 26th May 2026.
Announcement under Regulation 30 (LODR)-Change in Management
26-May-2026 | Source : BSERe-appointment of M/s NP Rajput & Co as Internal Auditor for FY 2026-27 at the Board Meeting held on 26th May 2026.
Board Meeting Outcome for Outcome Of The Board Meeting
26-May-2026 | Source : BSEAudited Financial Results (Standalone and Consolidated) for quarter and year ended 31st March 2026
Corporate Actions
No Upcoming Board Meetings
Eiko Lifesciences Ltd has declared 2% dividend, ex-date: 20 Sep 17
No Splits history available
No Bonus history available
Eiko Lifesciences Ltd has announced 2:3 rights issue, ex-date: 07 Jul 23